乌司他丁对脓毒症患者血清肿瘤坏死因子-α、白细胞介素10、肌钙蛋白I和C反应蛋白水平的影响
Effect of ulinastatin on the serum levels of tumor necrosis factor α, interleukin 10,troponin I and C-reactive protein
-
摘要: 目的：通过观察患者细胞因子水平的变化来探讨乌司他丁在脓毒症中的作用机制，旨在评价乌司他丁对人脓毒症的疗效,并评价肌钙蛋白I（cTnI）、C反应蛋白（CRP）用于脓毒症病情评价和预后评估的意义。方法：采用前瞻性对照研究，收集符合脓毒症诊断标准的患者60例，随机分为乌司他丁组和对照组。在相同的常规治疗基础上，乌司他丁组给予乌司他丁针20万U静脉注射，8 h 1次。对照组则给予同等量的0.9%氯化钠注射液。所有患者在治疗前和治疗后48 h、120 h，进行急性生理和慢性健康状况评分（APACHEⅡ评分），并测定血清肿瘤坏死因子α（TNF-α）、白细胞介素10（IL-10）、CRP、cTnI的水平，计算2组患者的28 d病死率。结果：治疗前2组患者血清TNF-α、IL-10、cTnI、CRP和APACHEⅡ评分治疗前差异均无统计学意义（P>0.05）。治疗后48 h、120 h乌司他丁组的TNF-α、CRP水平和APACHEⅡ评分均低于对照组（P<0.05～P<0.01）。治疗后48 h和120 h乌司他丁组的IL-10水平均明显高于对照组（P<0.01）。乌司他丁组患者治疗后48 h、120 h cTnI、CRP水平与APACHEⅡ评分均较治疗前明显下降（P<0.01）。2组28 d病死率差异无统计学意义（P>0.05）。结论：脓毒症患者应用乌司他丁治疗后虽不能降低28 d病死率，但可减轻脓毒症患者炎症反应，较快改善脓毒症患者病情，其机制可能为通过降低促炎因子TNF-α、升高抑炎因子IL-10水平实现的。Abstract: Objective: To explore the troponin I mechanism of action ulinastatin in sepsis patients by observing the change of cytokine,evaluate the efficacy of ulinastatin and significance of troponin I(cTnI) and C-reactive protein(CRP) in the disease condition and prognosis of sepsis.Methods: Sixty patients with sepsis were selected by the prospective controlled study,and randomly divided into the ulinastatin group(group A) and control group(group B).Based on the same conventional treatment,the group A were treated with 200,000 U ulinastatin by intravenous once 8 hours,and the group B were treated with the same amount of saline.Before treatment and after 48 h and 120 h of treatment,the acute physiology and chronic health evaluation scores(APACHE Ⅱ score) in all patients were investigated,the serum levels of tumor necrosis factor α(TNF-α),interleukin-10(IL-10),CRP and cTnI in two groups were detected,and the 28-day mortality in patients were calculate.Results: The differences of the serum levels of TNF-α,IL-10,cTnI and CRP,and the APACHE Ⅱ score between two groups before treatment were not statistically significant(P>0.05).After 48 h and 120 h of treatment,the levels of TNF-α,CRP and the APACHE Ⅱ score in group A were lower than those in group B(P<0.05 to P<0.01),and the level of IL-10 in group A was significantly higher than that in group B(P<0.01).Compared before treatment,the levels of cTnI and CRP,and the APACHEⅡ score in group A significantly decreased after 48 h and 120 h of treatment(P<0.01).The difference of the 28-day mortality between two groups was not statistically significant(P>0.05).Conclusions: The treatment of sepsis with ulinastatin can not reduce the 28-day mortality,but it can alleviate the inflammatory response,and improve the condition of patients,the mechanism of which may involve in decreasing the level of TNF-α and increasing the level of IL-10.
-
[1] ANGUS DC,LINDE-ZWIRBLE WT,LIDICKER J,et al.Epidemiology of severe sepsis in the United States:analysis of incidence,outcome,and associated cost of care[J].Crit Care Med,2001,29(7):1303. [2] VINCENT JL,SAKR Y,SPRUNG CL,et al.Sepsis in European intensive care units:results of the SOAP study[J].Crit Care Med,2006,34(2):344. [3] NAGAI S,ASOH S,KOBAYASHI Y,et al.Protection of hepatic cells from apoptosis induced by ischemia/reperfusion injury by protein therapeutics [J].Hepatology Res,2007,37(2):133. [4] VIEILLARD-BARON A,CAILLE V,CHARRON C,et al.Actual incidence of global left ventricular hypokinesia in adult septic shock[J].Crit Care Med,2008,36(6):1701. [5] ZAHAR JR,TIMSIT JF,CARROUSTE-ORGEAS M,et al.Outcomes in severe sepsis and patients with septic shock:Pathogen species and infection sites are not associated with mortality[J].Crit Care Med,2011,39(8):1886. [6] MIHAI GN,JOS WM,MARCEL VD,et al.Proinflammatory cytokines and sepsis syndrome:not enough,or too much of a good thing? [J].Trends Immunol,2003,24(5):254. [7] Dunn KL,Espino PS,Drobic B,et al.The Ras-MAPK signal transduction pathway,cancer and chromatin remodeling[J].Biochem Cell Biol,2005,83(1):1. [8] HOTCHKISS RS,KARL IE.The pathophysiology and treatment of sepsis[J].N EngI J Med,2003,348(2):138. [9] BABCOCK GF,WHITE-OWEN CL,ALEXANDER JW,et al.Characteristics of Neutrophil Dysfunction[M].// FAIST E,MEAKINS JL,SCHILDBERG FW.Host defense dysrunction in trauma,shock and sepsis.Berlin:Springer-Verlag,1993:95. [10] 方强,陈朴.乌司他丁对重症脓毒症患者的疗效及其作用机制的研究[J].中国抗感染化疗杂志,2005,5(1):13. [11] 孙荣青,张少雷.脓毒症早期血清白细胞介素-18和10在疾病严重程度及预后评估中的价值研究[J].中国危重病急救医学,2011,23(5):299. [12] 邵义明,张良清,邓烈华,等.乌司他丁对全身炎症反应综合征的治疗作用[J].中国危重病急救医学,2005,17(4):228. [13] 冯德光,金春华,薛翔,等.脓毒性心肌病大鼠的死亡特征及机制初探[J].中国危重病急救医学,2012,24(12):742. [14] 谭若铭,刘嘉琳,瞿洪平.生物标记物在成人脓毒症患者中的应用进展[J].中国危重病急救医学,2010,22(9):570. [15] CHOPRA M,SHARMA AC.Distinct cardiodynamic and molecular characteristics during early and late stage of sepsis-induced myocardial dysfunction[J].Life Sci,2007,81(4):306. [16] 赵静,秦俭,杨淑芳.C反应蛋白和临床肺部感染评分在老年社区获得性肺炎预后评估中的作用[J].首都医科大学学报,2007,28(4):450. [17] 颜默磊,严静,蔡国龙,等.早期目标性治疗对脓毒症患者血浆C反应蛋白及前降钙素水平的影响[J].中华急诊医学杂志,2009,18(1):79. -
点击查看大图
计量
- 文章访问数: 3531
- HTML全文浏览量: 279
- PDF下载量: 70
- 被引次数: 0
下载:
